Rie Io Glerup

Rie Io Glerup

Auto-generated profile, based on publicly available information

Rie Io Glerup

Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Kidney Medicine
Verified
Journal Article
Open access
RGRie Glerup
Rie Glerup
MSMy Svensson
My Svensson
JJJens D. Jensen
Jens D. Jensen
JCJeppe H. Christensen
Jeppe H. Christensen
Arteriovenous fistulas are the preferred access type for hemodialysis. The buttonhole needling technique has become an alternative to stepladder or area puncture. However, an increased risk for infection has been described. The present study examined the risk for infectious complications with different needling techniques. Prospective multicenter observational cohort study with 5 years of follow-up. In-center hemodialysis patients from 5 hemodialysis units in Denmark, dialyzed on a native arteriovenous fistula. 286 patients were included; 144 cannulated with the buttonhole technique. The buttonhole cannulation technique was compared to the stepladder or area puncture technique. Primary end points: event rates of access-related Staphylococcus aureus bacteremia and the HR for first access-related S aureus bacteremia. Secondary end points: local infections and access-related S aureus bacteremia–related metastatic infections and mortality. Time-to-event analysis using Cox proportional hazards regression to estimate the HR of access-related S aureus bacteremia in buttonhole cannulation compared to stepladder/area puncture. Poisson regression was used for incidence rate ratio calculations. S aureus caused 48 access-related bacteremias; 43 (90%) in the buttonhole group compared with 5 (10%) in the stepladder/area group. The HR for first access-related S aureus bacteremia was significantly higher for buttonhole cannulation compared to stepladder/area needling (unadjusted, 6.8 [95% CI, 2.4-19.1]; adjusted, 8.4 [95% CI, 2.9-24.2]). The incidence rate ratio for access-related S aureus bacteremia was 6.8 (95% CI, 2.9-16.1), and the incidence rate ratio of local cannulation-site infection without access-related S aureus bacteremia was 3.8 (95% CI, 1.3-15.4) for buttonhole cannulation compared to stepladder/area needling. Nonrandomized observational design, prevalent hemodialysis patients. Access-related S aureus bacteremia rates were very high for buttonhole cannulation compared to stepladder/area needling, questioning the use of buttonhole cannulation in routine clinical practice. A restrictive approach to buttonhole use is recommended, with buttonhole cannulation only being used as a second alternative to area technique when stepladder cannulation is not feasible.

22 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Ping-Hsun WuPing-Hsun Wu
Ping-Hsun Wu
RGRie Io Glerup
Rie Io Glerup
MSMy Svensson
My Svensson
NENiclas Eriksson
Niclas Eriksson
JCJeppe Hagstrup Christensen
Jeppe Hagstrup Christensen
BFBengt Fellström
Bengt Fellström
End-stage kidney disease increases mortality and the risk of cardiovascular (CV) disease. It is crucial to explore novel biomarkers to predict CV disease in the complex setting of patients receiving hemodialysis (HD). This study investigated the association between 92 targeted proteins with all-cause death, CV death, and composite vascular events (CVEs) in HD patients. From December 2010 to March 2011, 331 HD patients were included and followed prospectively for 5 years. Serum was analyzed for 92 CV-related proteins using Proseek Multiplex Cardiovascular I panel, a high-sensitivity assay based on proximity extension assay (PEA) technology. The association between biomarkers and all-cause death, CV death, and CVEs was evaluated using Cox-regression analyses. Of the PEA-based proteins, we identified 20 proteins associated with risk of all-cause death, 7 proteins associated with risk of CV death, and 17 proteins associated with risk of CVEs, independent of established risk factors. Interleukin-8 (IL-8), T-cell immunoglobulin and mucin domain 1 (TIM-1), and C-C motif chemokine 20 (CCL20) were associated with increased risk of all-cause death, CV death, and CVE in multivariable-adjusted models. Stem cell factor (SCF) and Galanin peptides (GAL) were associated with both decreased risk of all-cause death and CV death. In conclusion, IL-8, TIM-1, and CCL20 predicted death and CV outcomes in HD patients. Novel findings were that SCF and GAL were associated with a lower risk of all-cause death and CV death. The SCF warrants further study with regard to its possible biological effect in HD patients.

20 July 2026 in Kidney360
Verified
Journal Article
Open access
CDCaroline Liboriussen Drivsholm
Caroline Liboriussen Drivsholm
LNLouis Nygaard
Louis Nygaard
GDGertrud Dam-Dalgeir
Gertrud Dam-Dalgeir
RGRie Io Glerup
Rie Io Glerup
ABAllan Birnum
Allan Birnum
MSMy Svensson
My Svensson
Key Points: High-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, and N -terminal pro–B-type natriuretic peptide are reduced by hemodiafiltration, increasing the risk of potential misinterpretation in patients undergoing dialysis. Measuring these biomarkers during or immediately after dialysis may yield falsely low concentrations. Clinicians should consider the timing of the most recent dialysis session when interpreting cardiac biomarkers for diagnostic purposes. Background: There are limited data on how hemodialysis influences cardiac biomarker concentrations. This study aimed to investigate concentration changes of high-sensitivity troponin I and T, and N -terminal pro–B-type natriuretic peptide (NT-proBNP) before, during, and after hemodialysis and hemodiafiltration (HDF), and to compare these changes between the two dialysis modalities. Methods: Randomized crossover study including 23 stable patients treated with hemodialysis/HDF. Patients were randomized to start with high-flux hemodialysis or postdilution HDF, had a washout period of 1–3 weeks, and then crossed over to receive the other modality. Blood samples were collected before dialysis, after 10, 30, 60, 120, 180, and 240 minutes of dialysis, and 30 minutes postdialysis. In addition, spent dialysate was collected after 120 minutes of dialysis. Linear mixed-effects models were used to investigate concentration changes and compare dialysis modalities. Results: High-sensitivity troponin I and high-sensitivity troponin T were not influenced by hemodialysis; however, HDF resulted in a significant decline in both biomarkers. At the end of dialysis, the change was −7.7 ng/L (95% confidence interval [CI], −12.3 to −3.1) for high-sensitivity troponin I and −23.4 ng/L (95% CI, −31.8 to −15.0) for high-sensitivity troponin T. NT-proBNP was significantly reduced with both modalities, with a change of −2954 ng/L (95% CI, −4974 to −934) in hemodialysis and −5161 ng/L (95% CI, −7231 to −3092) in HDF. All biomarker concentrations were significantly lower with HDF compared with hemodialysis at the end of dialysis. Conclusions: High-sensitivity troponin I, high-sensitivity troponin T, and NT-proBNP were significantly reduced with HDF in asymptomatic patients treated with dialysis. Hemodialysis reduced NT-proBNP. Cardiac biomarker levels are influenced by dialysis and treatment modality, which could lead to potential misinterpretation. This emphasizes that time since the last dialysis session should be considered when interpreting cardiac biomarkers for diagnostic purposes. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT06526702.

29 December 2021 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
RGRie Glerup
Rie Glerup
MSMy Svensson
My Svensson
LJLasse H. Jakobsen
Lasse H. Jakobsen
BFBengt Fellstrøm
Bengt Fellstrøm
JJJens D. Jensen
Jens D. Jensen
JCJeppe H. Christensen
Jeppe H. Christensen